[CAS NO. 1638611-48-9] JC124
PRODUCTS SPECIFICATIONS [1638611-48-9]
DESCRIPTION [1638611-48-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 382.86 |
| Molecular Formula | C17H19ClN2O4S |
| SMILES | O=C(C1=CC(Cl)=CC=C1OC)NCCC2=CC=C(C=C2)S(=O)(NC)=O |
Summary
In Vitro
JC124 shows selective inhibition of NLRP3 inflammasome formation and activation of caspase-1, and reduction of IL-1β both in vitro [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
JC124 (100 mg/kg; i.p.; 4 doses; 30 min post-injury, 6, 24, and 30 h after TBI) treatment significantly decreases the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume. JC124 also significantly reduces protein expression levels of NLRP3, ASC, IL-1 beta, TNFα, iNOS, and caspase-1 [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Adult male Sprague-Dawley rats (3-4-months-old) bearing traumatic brain injury (TBI) [1] |
| Dosage: | 100 mg/kg |
| Administration: | i.p.; 4 doses; 30 min post-injury, 6, 24, and 30 h after TBI |
| Result: | Significantly decreased the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 250 mg/mL ( 652.98 mM ; ultrasonic and adjust pH to 3 with HCl)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.6119 mL | 13.0596 mL | 26.1192 mL |
| 5 mM | 0.5224 mL | 2.6119 mL | 5.2238 mL |
| 10 mM | 0.2612 mL | 1.3060 mL | 2.6119 mL |